Evidence map›Paper›PMID 41220797›Full record

ArticleMolecular and clinical oncology2025

High expression of CDKN2A in oral squamous cell carcinoma is associated with distant metastasis: Cell-free DNA as a new prognostic feature.

Natsuki Eboshida, Atsuko Hamada, Asami Tanigawa, Mirai Higaki, Fumitaka Obayashi, Nanako Ito, Sachiko Yamasaki, Ryouji Tani, Tomoaki Shintani, Koichi Koizumi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natsuki EboshidaDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Atsuko HamadaDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Asami TanigawaDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Mirai HigakiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Fumitaka ObayashiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Nanako ItoDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Sachiko YamasakiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Ryouji TaniDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Tomoaki ShintaniCentre of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima 734-8553, Japan.
Koichi KoizumiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Souichi YanamotoDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) shows a high incidence and is associated with a higher rate of mortality, particularly in developing countries. Although the development of treatment strategies has been remarkable, the 5-year survival rate remains low (often <50%). Surgery and chemoradiotherapy are the standard treatments; however, there are limited factors that can predict metastasis. Liquid biopsy is promising in treating various cancers, including OSCC. In previous studies on OSCC, associations were identified among circulating tumour cell clusters, cell-free DNA (cfDNA) size/quantity and prognosis. The present study aimed to explore the role of CDKN2A and TP53 in OSCC using immunohistochemistry. Next-generation sequencing analysis of both cfDNA and tissues from two patients with poor prognoses was performed, and two common mutated genes,

Indexed as

CDKN2AcfDNAimmunohistochemistryliquid biopsynext-generation sequencingoral squamous cell carcinomaTP53

Identifiers

PMID41220797
PMCPMC12598524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.